title: Effects of lisinopril and nitrendipine on urinary albumin excretion and renal function in patients with mild to moderate essential hypertension.
abstract: The present study was designed to evaluate the effects of an ACE inhibitor, lisinopril, and a calcium antagonist, nitrendipine, on urinary albumin excretion (UAE) and renal function in mild to moderate essential hypertensive patients with microalbuminuria. After the 4-week drug-free period, 17 patients were randomly divided into two groups. The first group (group 1: n=8) received lisinopril 10-20 mg daily for 8 weeks followed by nitrendipine 5-10 mg daily for another 8 weeks. The second group (group 2: n=9) received nitrendipine 5-10 mg daily for 8 weeks followed by lisinopril 10-20 mg daily for another 8 weeks. The mean blood pressure (MBP) significantly decreased in a similar manner in both groups. UAE significantly decreased after 8 weeks of treatment with lisinopril in group 1 and after 8 weeks of subsequent treatment with lisinopril in group 2. On the other hand, UAE was not altered by treatment with nitrendipine. The changes in UAE were significantly correlated with changes in MBP after 8 weeks of treatment with nitrendipine, but not after 8 weeks of treatment with lisinopril. No significant changes in creatinine clearance, urinary excretion of sodium or urinary N-acetyl-beta-D-glucosaminide were observed by any treatment in either group. These results suggest that lisinopril, not nitrendipine, reduces UAE in essential hypertensive patients with microalbuminuria independently of its effective antihypertensive properties.
authors.affiliation: Asahikawa Medical College, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Haneda
authors.forename: T
authors.initials: T
authors.lastname: Hirayama
authors.forename: H
authors.initials: H
authors.lastname: Ide
authors.forename: A
authors.initials: A
authors.lastname: Obara
authors.forename: J
authors.initials: J
authors.lastname: Maruyama
authors.forename: H
authors.initials: H
authors.lastname: Morimoto
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: J
authors.initials: J
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Hayakawa
authors.forename: N
authors.initials: N
authors.lastname: Hasebe
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
mesh_terms: D000419:Albuminuria / Q000652:urine*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology* / Q000652:urine*; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D009568:Nitrendipine; D017706:Lisinopril